Innofurix Tablet (Inosiphlex)

Adult dosage

(Tablets) Adults: Administer 3～4 g of inosiplex daily orally in divided doses of 500 mg～1 g every 4～6 hours. (Syrup) Adults: Administer 3～4 g daily (60～80 mL of this medicine) orally in divided doses of 500 mg～1g (10～20 mL) every 4～6 hours.

Children's dosage

(Tablets) Children: Administer 50～100 mg per kg of body weight daily of this medicine orally in 6 divided doses. (Syrup) Children: Administer 50～100 mg per kg of body weight daily orally in 6 divided doses.

This medication should not be administered to patients who have had an allergic reaction to it or any of its components. Patients with gout or hyperuricemia, or a history of such conditions, should use this medication with caution, as it may exacerbate symptoms by increasing blood uric acid levels. Patients with urinary stones or kidney stones should also use this medication carefully, as it may increase uric acid levels in the blood or urine, worsening stone symptoms. Patients with impaired kidney function should be cautious with this medication, as it may delay uric acid excretion and lead to side effects. Patients taking cardiac medication digoxin should administer this medication carefully, as it may exhibit slight cardiac activity. Taking this medication may cause gastrointestinal symptoms such as dyspepsia, diarrhea, constipation, nausea, vomiting, and abdominal pain. There may also be hematological abnormalities such as increased red blood cell count, decreased white blood cells, and increased platelets. Liver function tests may show elevated levels, so attention to liver health is advised. Allergic reactions such as skin rashes may occur infrequently. This medication may elevate blood uric acid levels and potentially induce hyperuricemia. Effects on the kidneys and urinary tract may lead to elevated blood urea nitrogen (BUN), kidney stones due to hypercalcemia, increased urine volume, and urinary stones. Neurological symptoms like headaches, dizziness, fatigue, malaise, irritability, drowsiness, and insomnia may also occur. Joint pain or, rarely, interstitial pneumonia may also present; any symptoms should be reported immediately. As this medication may increase uric acid levels in the blood and urine, regular monitoring of uric acid levels and kidney function during treatment is recommended. While there are no specific severe drug interactions with this medication, it is advisable to avoid taking it with cortisone, globulin, immunosuppressants, or anti-lymphocyte globulin. The safety of this medication during pregnancy has not been established, so it is recommended to avoid use during the first three months of pregnancy; if administration during pregnancy is necessary, it should only be after consulting a physician when the benefits outweigh the risks. Animal studies have shown that this medication is excreted in breast milk, so it is preferable to discontinue use while nursing. In cases of overdose, symptoms such as vomiting, headaches, upper abdominal discomfort, dizziness, and palpitations may occur; however, reducing the dosage or discontinuing use will resolve the symptoms. In cases of overdose, symptomatic and supportive treatment should be implemented.

abdominal discomfort, diarrhea, constipation, gastrointestinal bleeding, nausea, vomiting, stomach pain, increased red blood cells, decreased white blood cells, increased platelets, elevation of AST/ALT, elevation of γ-GTP, elevation of ALP, elevation of LDH, rash, hyperuricemia, elevated BUN, kidney stones associated with hypercalcemia, polyuria, urinary stones, headache, dizziness, fatigue, malaise, irritability, drowsiness, insomnia, arthralgia, interstitial pneumonia, palpitations

This medication should be stored in a tightly closed container that blocks light and prevents air from entering. It should also be stored at room temperature, avoiding excessively hot or cold locations.

Appearance

This medication is a white or off-white tablet.

Package unit

8, 60, 120, 500 tablets